Drugs.com New Drug ApplicationsOriginal article
Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026
NDA FilingSL1009Positive
AI Analysis
Summary
Saol Therapeutics announced FDA acceptance of a resubmission for SL1009 (DCA) with a PDUFA decision date of December 30, 2026. The regulatory action represents progress toward potential approval of the drug candidate.
Outcome Details
Resubmission accepted by FDA
Importance:7/10
Sentiment:
0.60
FDAPDUFANDA resubmissionregulatory
Read the original article
Published by Drugs.com New Drug Applications on July 28, 2026 1:07 AM